Europe led the biosimilar market since 2006 with clear regulations and fast adoption. The U.S. lagged due to legal and regulatory barriers - until 2024, when the FDA removed key roadblocks. Now, the U.S. is racing to catch up, with biosimilars poised to save billions in healthcare costs.
Read More